Neogen Chemicals share price today

Neogen Chemicals Ltd's share price was ₹2,273.60 at the close on 4 November 2026. It has been rising for 26 weeks. That is 16.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,055 and ₹2,488, and at that close it sat 85% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Neogen Chemicals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 7.5 years the share price moved +768% while the NIFTY 500 moved +139%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

7 points in one quarter and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 10 quarters in a row

   In the September 2026 quarter revenue was ₹296 crore, +41.8% on a year earlier.

2. Promoters cut their stake by 4.7 points in one quarter

   From 53% to 48.3% in the September 2026 quarter.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹296 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Neogen Chemicals reported revenue of ₹296 crore, up 41.8% from ₹209 crore a year earlier, and a profit of ₹8.23 crore, up 144.2% from ₹3.37 crore.

Neogen Chemicals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 28 September 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Neogen Chemicals closed at ₹2,273.60 on 4 November 2026, up 56.6% from ₹1,452.30 a year earlier (7 November 2025) and up 80.7% over five years. Its highest weekly close since May 2019 was ₹2,488.40 on 18 September 2026.

Neogen Chemicals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

399 weekly closes from 10 May 2019 to 4 November 2026.

4 Nov 2026: Neogen Chemicals closed at ₹2,273.60, up 4.7% on the week and down 5.5% on the month. Results for July to September 2026: Revenue up 41.8% and profit up 144.2% on a year earlier.

Earlier

• 28 Sep 2026: Neogen Chemicals held its results call for April to June 2026. Management guided: Base-company revenue ₹1,050 crore this year.
• 13 Aug 2026: ex-date for a dividend of ₹1 a share.

Neogen Chemicals paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.04% at the ₹2,273.60 close on 4 November 2026. The last was a dividend of ₹1 a share, ex-date 13 August 2026.

Neogen Chemicals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Neogen Chemicals Ltd paid out 18% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 28 September 2026, Neogen Chemicals' management guided: Base-company revenue ₹1,050 crore this year.

“I would say that only some purchase orders for the current quarter, and perhaps some for the next quarter, for electrolyte salt or similar products are legally binding take-or-pay-type contracts. The rest of the revenue projection is based on the assumptions I explained earlier. - Dr. Harin Kanani”Managing Director, on the call for April to June 2026

What management guided

• Battery revenue approximately ₹300 crore this year and above ₹1,000 crore next year.
• FY29 battery revenue ₹2,500-3,000 crore and consolidated revenue ₹3,500-4,000 crore.
• Nearly ₹1,800 crore of battery capital spending to complete by year-end, covering Dahej capacity up to 2,500 tons of salt/additives and Pakhajan capacity of 30,000 tons of electrolyte plus 3,000 tons of salt; full utilization within two years.
• No take-or-pay contracts for most volumes; international salt customers indicated at least 40% purchase, which management linked to 70-80% salt-capacity utilization and ₹700-800 crore revenue.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 28 September 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Neogen Chemicals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Pakhajan commissioning and the remaining US electrolyte approval - check recipe validation and customer qualification progress.

Neogen Chemicals is not on any of our India lists this week.

Neogen Chemicals Ltd earned ₹8.2 Cr of net profit in the Sep 2026 quarter, +144.2% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹29.0 Cr. Over 10 years profit has grown 19.2% a year on average. That is 2.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹3.4 Cr.

For the full year, FY26 profit was ₹29.0 Cr (−17.1% on the year before).

Why profit moved: revenue changed +41.8% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +130.1% and revenue +26.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Neogen Chemicals Ltd reported ₹296 Cr of revenue in the Sep 2026 quarter, +41.8% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 24.0% a year on average. The last full year, FY26, came in at ₹862 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,013 Cr.

FY26 revenue was ₹862 Cr, +10.8% on the year before.

Recent pace: the last four quarters grew +26.6% on average, against 24.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +26.7%, against +17.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +55.2%, against +0.0% a year (accelerating).

Neogen Chemicals Ltd's operating margin was 15.3% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 14.0% and 19.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.0 percentage points on the year while gross margin changed −1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years Neogen Chemicals Ltd's operations used more cash than they brought in, so cash conversion was −64%, a gap worth watching. In FY26 its operations used ₹231 Cr of cash, against ₹29.0 Cr of profit. After ₹800 Cr of spending on assets, free cash was −₹1,031 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −64% of profit came in as cash: the cash cycle got 86 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 86 days longer. The next section looks at where the cash is stuck.

Neogen Chemicals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 260 days in FY26, up from 174 days in FY21. It spent ₹1,028 Cr on assets over the last 3 years. Customers take 161 days to pay, and stock sits for 445 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹862 Cr, each day of that cycle ties up about ₹2.4 Cr, so roughly ₹614 Cr is tied up in the business at any time.

FY26: customers took 161 days to pay and stock sat for 445 days, about 14.6 months of sales sitting as stock, for a full cycle of 260 days, longer than FY21's 174.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 445 days. Customers pay about 161 days after that. Suppliers are paid at 346 days. Together that makes the 260-day cycle.

Spending on assets: ₹1,028 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹857 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Neogen Chemicals Ltd's P/E is 168.6×, near the high end of its own history: higher than 92% of past readings. Its usual P/E (the middle reading) is 82.9×, over 7.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹14.71.

Why the multiple is where it is: over the past year earnings per share moved −17.4% while the price moved +56.6%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +12.6% a year; about −3.3% a year came from earnings growth and about +15.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Neogen Chemicals Ltd's business is getting better. EPS growth hit its low 3 quarters ago at −35.6% and has recovered to +49.0%, with ROCE steady at 9.8%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: a lasting rise from a low is what this page is built to show.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Neogen Chemicals Ltd earned a ROCE of 6% in FY26. Its return on capital used (ROIC) is 8.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.4% net margin and 0.30× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 3.4% net margin × 0.30× asset turnover × 3.56× leverage (assets divided by equity) ≈ 3.6% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 4.0% − 12.0% = −8.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Neogen Chemicals Ltd has total debt of ₹1,395 Cr against shareholder equity of ₹816 Cr as of Jun 2026, so its debt is 1.71× its equity. Year by year, that ratio went from 0.52 in FY22 to 1.71 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.